# Douglas Dieter

> Douglas Dieter is a post-ipo debt investor at Ares Management backing Medical and Biopharma. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ares Management](https://shizune.co/investors/profile/ares-management)
- Location: Los Angeles, United States
- Total investments: 1
- Last investment: Feb 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/douglas-dieter-dr-p-h-0577662

Douglas Dieter is a post-ipo debt investor at Ares Management in Los Angeles focused on Medical and Biopharma. Douglas Dieter is the partner at Ares Management Corporation. Douglas Dieter attended Georgetown University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Biopharma | 1 | 100% |
| Life Science | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amryt Pharma | Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.Amryt’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intendsto further develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S.Amryt’s earlier-stage products are focussed on developing novel, next-generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there are high unmet medical needs. These include acromegaly and Cushing's disease. | $125M | Post-IPO Debt | Feb 22, 2022 |  |

1 of 1 investments shown.

## About Ares Management

VC Fund · Chicago, United States

Ares Management is a publicly-traded global alternative asset manager with approximately $144 billion of assets under management. It believes each of its distinct but complementary investment groups in credit, private equity, and real estate is a market leader based on assets under management and investment performance.

5 contacts available at Ares Management.

| Name | Title | Profile |
| --- | --- | --- |
| Andres Pinter | Managing Director | https://shizune.co/investors/profile/andres-pinter |
| Barry M Miller | Chief Executive Officer | https://shizune.co/investors/profile/barry-m-miller |
| Bennett Rosenthal | Co-Founder, Co-Head, Senior Partner and Director | https://shizune.co/investors/profile/bennett-rosenthal |
| David Kaplan | Co-Founder, Director, and Partner | https://shizune.co/investors/profile/david-kaplan-c8ed |
| Douglas Dieter | Partner | https://shizune.co/investors/profile/douglas-dieter-3593 |

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does Douglas Dieter invest in?

Douglas Dieter invests primarily in Medical, Biopharma and Life Science startups, most often at Post-IPO Debt stage. Most of the 1 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Douglas Dieter last invest?

The most recent investment recorded for Douglas Dieter closed in Feb 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co